Concept of Combinatorial De Novo Design of Drug‐like Molecules by Particle Swarm Optimization
暂无分享,去创建一个
Markus Hartenfeller | Ewgenij Proschak | Andreas Schüller | Gisbert Schneider | G. Schneider | E. Proschak | M. Hartenfeller | A. Schüller
[1] G. Schneider,et al. Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. , 2007, Journal of medicinal chemistry.
[2] G. Schneider,et al. Protein Folding Simulation by Particle Swarm Optimization , 2007 .
[3] Hans Matter,et al. Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. , 2006, Journal of medicinal chemistry.
[4] Gisbert Schneider,et al. SMILIB: Rapid Assembly of Combinatorial Libraries in SMILES Notation , 2003 .
[5] Michael M. Hann,et al. RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..
[6] Alex Alves Freitas,et al. A new discrete particle swarm algorithm applied to attribute selection in a bioinformatics data set , 2006, GECCO.
[7] Walter Cedeño,et al. Using particle swarms for the development of QSAR models based on K-nearest neighbor and kernel regression , 2003, J. Comput. Aided Mol. Des..
[8] Petra Schneider,et al. Scaffold-Hopping: How Far Can You Jump , 2006 .
[9] Schmid,et al. "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. , 1999, Angewandte Chemie.
[10] Petra Schneider,et al. Comparison of correlation vector methods for ligand-based similarity searching , 2003, J. Comput. Aided Mol. Des..
[11] Gisbert Schneider,et al. Flux (2): Comparison of Molecular Mutation and Crossover Operators for Ligand-Based de Novo Design , 2007, J. Chem. Inf. Model..
[12] Li-Yeh Chuang,et al. Improved binary PSO for feature selection using gene expression data , 2008, Comput. Biol. Chem..
[13] Riccardo Poli,et al. Particle swarm optimization , 1995, Swarm Intelligence.
[14] Russell C. Eberhart,et al. A discrete binary version of the particle swarm algorithm , 1997, 1997 IEEE International Conference on Systems, Man, and Cybernetics. Computational Cybernetics and Simulation.
[15] G. Etgen,et al. PPAR ligands for metabolic disorders. , 2003, Current topics in medicinal chemistry.
[16] Gisbert Schneider,et al. Scaffold‐Hopping: How Far Can You Jump? , 2006 .
[17] Millard H. Lambert,et al. Asymmetry in the PPARγ/RXRα Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors , 2000 .
[18] Valerie J. Gillet,et al. SPROUT: A program for structure generation , 1993, J. Comput. Aided Mol. Des..
[19] Amedeo Caflisch,et al. Fragment-Based de Novo Ligand Design by Multiobjective Evolutionary Optimization , 2008, J. Chem. Inf. Model..
[20] W. Guida,et al. The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.
[21] T. Willson,et al. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. , 2000, Molecular cell.
[22] Gisbert Schneider,et al. Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.
[23] D. Agrafiotis,et al. Feature selection for structure-activity correlation using binary particle swarms. , 2002, Journal of medicinal chemistry.
[24] Bernard Pirard,et al. Peroxisome Proliferator-Activated Receptors target family landscape: A chemometrical approach to ligand selectivity based on protein binding site analysis , 2003, J. Comput. Aided Mol. Des..
[25] Matthias Rarey,et al. FlexNovo: Structure‐Based Searching in Large Fragment Spaces , 2006, ChemMedChem.
[26] Petra Schneider,et al. De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks , 2000, J. Comput. Aided Mol. Des..
[27] Kirsch,et al. Virtual Screening for Bioactive Molecules by Evolutionary De Novo Design Special thanks to Neil R. Taylor for his help in preparation of the manuscript. , 2000, Angewandte Chemie.
[28] Gisbert Schneider,et al. Molecular design . Concepts and applications , 2009 .
[29] T. Klabunde,et al. GPCR Antitarget Modeling: Pharmacophore Models for Biogenic Amine Binding GPCRs to Avoid GPCR‐Mediated Side Effects , 2005, Chembiochem : a European journal of chemical biology.
[30] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[31] Hans-Joachim Böhm,et al. The computer program LUDI: A new method for the de novo design of enzyme inhibitors , 1992, J. Comput. Aided Mol. Des..
[32] Philip M. Dean,et al. A validation study on the practical use of automated de novo design , 2002, J. Comput. Aided Mol. Des..
[33] M. Lambert,et al. Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. , 2007, Journal of medicinal chemistry.
[34] Gisbert Schneider,et al. Collection of bioactive reference compounds for focused library design , 2003 .
[35] Peter J. B. Hancock,et al. An Empirical Comparison of Selection Methods in Evolutionary Algorithms , 1994, Evolutionary Computing, AISB Workshop.
[36] Yue Shi,et al. A modified particle swarm optimizer , 1998, 1998 IEEE International Conference on Evolutionary Computation Proceedings. IEEE World Congress on Computational Intelligence (Cat. No.98TH8360).
[37] L. Moore,et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.